Will Hanmi Pharm start to develop modified drug of ‘Evista’?
Hanmi Pharm is about to jump in the development of incrementally modified drug of Evista(generic name: raloxifene), an osteoporosis therapy.
Hanmi Pharm was confirmed to file a defensive confirmation trial for the scope of the ‘Drugs Containing Benzothiophene and Methods’(March 20, 2017) patent ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
